Tracey Evans Chan is an Associate Professor and Director of the NUS Law Academy at the National University of Singapore's Faculty of Law. His expertise lies in biomedical law and ethics, with a focus on issues such as surrogacy, transplant ethics, and human-animal research. He has held significant roles, including a secondment to Singapore's Ministry of Health, where he contributed to the Human Biomedical Research Act 2015. He currently serves on the National Medical Ethics Committee and the Advisory Committee on Restricted Research under the same Act, and is a member of NUS's Institutional Review Board. Education: LLM (Harvard University) LLB (National University of Singapore) Research Interests: Chan's work bridges legal and ethical dimensions of biomedical advancements. Key areas include regulatory challenges in mitochondrial replacement technology, consent frameworks for minors, and the ethical implications of emerging medical technologies. His contributions to Singapore's legal committees reflect his commitment to balancing innovation with societal values. Publications & Trends: His recent works explore themes like advance care planning, the placebo effect in clinical practice, and cross-jurisdictional comparisons of healthcare dependency laws. These publications underscore his interdisciplinary approach to legal and biomedical challenges. Awards & Grants: No specific awards or grants are listed, but his policy contributions and academic output highlight his impactful work in regulatory frameworks. Advising & Teams: As a faculty member, he teaches courses like Medical Law and Ethics. His involvement in NUS's Institutional Review Board and Singapore's advisory committees demonstrates his role in shaping research ethics and healthcare policy.
Dr. Steven G. Clarke is a Distinguished Professor at UCLA Department of Chemistry & Biochemistry and director of research at the Molecular Biology Institute . His work bridges protein chemistry , methylation biology , and aging research through studies of spontaneous protein damage and its repair mechanisms. Education: BA in Chemistry and Zoology, Pomona College (magna cum laude, Phi Beta Kappa) PhD in Biochemistry and Molecular Biology, Harvard University (NSF Fellow) Postdoctoral Fellowship at UC Berkeley (Miller Fellow) Dr. Clarke's research focuses on protein isoaspartyl repair via PCMT1/PIMT enzymes , ribosomal protein methylation in Saccharomyces cerevisiae , and PRMT family characterization including PRMT7 and PRMT9. His lab combines biochemical assays , genetic models , and structural analysis to investigate aging mechanisms and disease implications. Recent publications highlight: COQ5 structure-function analysis in coenzyme Q biosynthesis PCMTD1 ubiquitin ligase interactions PRMT7 substrate specificity in histone H2B Protein isoaspartyl impacts on T cell function in lupus Novel PRMT inhibitors for cancer therapy Methionine addiction in osteosarcoma malignancy Major scientific awards: American Chemical Society Ralph F. Hirschmann Award in Peptide Chemistry NIH MERIT Award Ellison Medical Foundation Senior Scholar Award William C. Rose Award, ASBMB UCLA Distinguished Teaching Award (Eby Award winner) Current lab members include PhD candidates Eric Pang (UCSB) and Sining "Cindy" Wang (UCLA), while undergraduates Celeste Medina-Seymoure , Elizabeth Oroudjeva , Olivia Pacheco , and Jasmine Winter contribute to ongoing proteostasis studies. Collaborations with Profs. Jose Rodriguez and Catherine Clarke demonstrate interdisciplinary research approaches.
Dr. Ahmet Acar is an Associate Professor at the Department of Biological Sciences, Middle East Technical University (METU), Ankara, Turkey. He leads the Cancer Precision Medicine and Drug Resistance Laboratory, focusing on understanding mechanisms of drug resistance in cancer. His research integrates experimental models, next-generation sequencing, and deep learning to address clinical challenges in cancer therapy. Dr. Acar holds a B.Sc. from METU's Biological Sciences department and a Ph.D. from the Cancer Research UK Manchester Institute. He completed postdoctoral training at the Institute of Cancer Research, London, and the University of Manchester. Research Interests: Drug resistance mechanisms, precision oncology, tumor microenvironment modeling, patient-derived organoids, computational pathology, and evolutionary cancer biology. His lab develops 2D/3D co-culture systems, PDO biobanks, and AI-driven histopathology tools to improve treatment strategies. Recent Work Trends: Recent publications emphasize tumor evolution modeling, matrix mechanics in drug resistance, and AI applications in histopathology. Collaborations with hospitals in Turkey and Europe support PDO biobank initiatives. His team explores evolutionary steering strategies to exploit collateral drug sensitivities. Labs/Teams: Precision Medicine and Drug Resistance Lab at METU focuses on interdisciplinary approaches combining wet-lab experiments with computational methods. Current projects include ex vivo tumor modeling and AI-driven diagnostic tools for oncology.
Dr. Xiaoxiao Li is an Assistant Professor in the Electrical and Computer Engineering Department at the University of British Columbia (UBC), with joint appointments in Computer Science (Associate Member) and the School of Medicine at Yale University (Adjunct Assistant Professor). She is also a Canada CIFAR AI Chair and Canada Research Chair (Tier II) in Responsible AI. Her research focuses on enhancing trustworthiness, fairness, and efficiency in AI algorithms and foundation models, particularly in healthcare applications. Education: B.S. (Honors) in Zhejiang University (2015), Ph.D. in Biomedical Engineering from Yale University (2020), Postdoc at Princeton University (2020-2021). She leads the Trusted and Efficient AI (TEA) Lab at UBC, which develops algorithms for federated learning, medical imaging analysis, and interpretable AI systems. Research interests include federated learning, generative models, medical image analysis, AI fairness, and graph-based methods for neuroimaging. Recent projects include GMValuator (data valuation for generative models), FairMedFM (fairness benchmarking in medical AI), and FedTextGrad (textual gradient-based FL optimization). Grants: Canada Foundation for Innovation Grant (2023), UBC Green Lab Fund (2023), Vector Institute funding Teaching: Courses on machine learning, federated learning, and AI ethics at UBC Awards & Recognition: Best Paper Award at FL@FM WWW 2024, Editorial Board Member of Medical Image Analysis , multiple top-tier conference acceptances (NeurIPS, ICLR, CVPR, MICCAI). Lab & Teams: TEA Lab collaborates with industry and hospitals to translate AI research into clinical tools. Current projects address AI fairness in healthcare, federated learning for medical data, and multimodal medical analytics.
Owen R. White is a Professor in the Department of Epidemiology & Public Health at the University of Maryland School of Medicine, serving as Associate Director of the Institute for Genome Sciences and Associate Director of Research Collaboration & Development. He leads a team of 25 scientists and engineers developing genomic annotation pipelines and data analysis tools for state-of-the-art research in microbiome and multi-omic studies. His academic background includes: BS in Biotechnology from the University of Massachusetts (1985) PhD in Molecular Biology from New Mexico State University (1992) Postdoctoral Fellowship in Genome Informatics at the Institute for Genomic Research (TIGR) (1994) Dr. White's research spans bioinformatics, genomics, transcriptomics, and metagenomics with emphasis on data management, metadata standards, ontologies, and cloud systems. His work has been foundational for large-scale initiatives like the Human Microbiome Project (HMP) and Integrative Human Microbiome Project (iHMP), generating over 50,000 datasets totaling 10 terabytes of multi-omic data. Analysis of his recent publications reveals a strong trend toward neuroscience multi-omics (BRAIN Initiative), cloud-based data infrastructure, and ethical data sharing frameworks. His work consistently bridges microbiome research with emerging fields like single-cell analysis and Alzheimer's disease biomarker discovery through integrated data platforms. Notable awards include: Benjamin Franklin Award for Open Access in the Life Sciences (2015) Kumho Science International Award in Plant Molecular Biology and Biotechnology (2001) As Principal Investigator for major NIH-funded centers, he has secured sustained support for the HMP Data Analysis and Coordination Center and iHMP Data Coordination Center. His team's work combines fee-for-service models with collaborative research funding to maintain cutting-edge genomic analysis capabilities. The Institute for Genome Sciences houses his computational team responsible for developing production annotation pipelines, database systems, and visualization tools that serve researchers across the University of Maryland School of Medicine and national consortia.
Professor Matthias Mann is a world-leading scientist serving as Director of the Proteomics and Signal Transduction department at the Max Planck Institute of Biochemistry in Martinsried, Germany, and Director of the Proteomics department at the Novo Nordisk Foundation Center for Protein Research, Faculty of Health Sciences, University of Copenhagen, Denmark. With an h-index exceeding 277 and over 350,000 citations, he is recognized as the highest cited German researcher and one of the most influential scientists globally in proteomics. His educational background includes: Ph.D. in Chemical Engineering from Yale University (1988) Master's Degree in Physics from Georg August University Göttingen (1984) Bachelor's of Arts in Mathematics from Georg August University Göttingen (1982) Professor Mann's research focuses on advancing mass spectrometry-based proteomics to understand biological systems at the protein level. His work spans technological developments in mass spectrometry, bioinformatics and computational analysis, signal transduction and posttranslational modifications, and clinical proteomics applications for disease diagnosis and treatment. The Mann lab has pioneered groundbreaking methods like SILAC for quantitative proteomics and MaxQuant for proteome data analysis. Their vision is to translate proteomics knowledge into clinical practice for predictive, diagnostic, and preventive medicine, with recent work focusing on AI-guided platforms for analyzing proteomes from minimal tissue samples. Analysis of Professor Mann's recent publications reveals a strong trend toward clinical applications of proteomics, particularly in cancer research, metabolic diseases, and neurodegenerative disorders. His work increasingly integrates spatial proteomics, single-cell resolution techniques, and artificial intelligence approaches to uncover disease mechanisms and identify potential biomarkers, with a clear shift from basic technology development toward direct clinical applications and personalized medicine. Professor Mann has received numerous prestigious awards throughout his career: 2025: Elected member of the American National Academy of Sciences 2024: Dr. H.P. Heineken Award for Biochemistry and Biophysics 2023: Otto Warburg Medal 2019: Nominated member of the Bavarian Academy of Sciences 2013: Elected member of Leopoldina German National Academy of Sciences 2012: Körber European Science Award, Louis-Jeantet Foundation Prize for Medicine, Ernst Schering Prize, and Leibniz Prize Professor Mann leads a highly collaborative research team involved in multiple international networks including the Bill & Melinda Gates Foundation, Michael J. Fox Foundation for Parkinson's Research, CLINSPECT-M, and Munich Heart Alliance. His lab has mentored numerous successful researchers, with several former postdocs receiving prestigious ERC Starting Grants. The Mann group has developed innovative clinical proteomics pipelines for analyzing archived tissue specimens and body fluids, aiming to identify protein markers for early detection of diseases such as diabetes and cancer. The Mann lab operates across two major research centers with state-of-the-art mass spectrometry facilities. Their Clinical Knowledge Graph platform integrates multi-omics data with extensive metadata, creating an ecosystem for machine learning applications in proteomics. Current research focuses on developing highly sensitive methods that can profile thousands of proteins from minimal cell samples, enabling the identification of critical disease-related proteins and supporting the development of individualized therapies.
Sushmita Roy is a Professor at the University of Wisconsin–Madison, affiliated with the Department of Computer Sciences and the College of Letters and Science. Her research focuses on developing computational methods in statistical machine learning to understand gene regulatory networks in living cells, particularly under environmental, developmental, disease, and evolutionary contexts. She explores bulk and single-cell genomic data integration to study processes like cell fate specification, host-microbe interactions, and diseases such as cancer and neurodevelopmental disorders. Her work emphasizes three key areas: inference of genome-scale transcriptional networks, evolutionary analysis of regulatory networks, and 3D genome organization dynamics. Roy’s lab collaborates across disciplines, leveraging genomic data from plant and mammalian systems. She has contributed to methodologies for analyzing chromatin accessibility, single-cell profiling, and network-based models of pathogen systems. Her affiliations include Wisconsin Institutes for Discovery, and she is a leader in computational biology and systems genomics research.
Prof. Dr. Helmuth Gehart is a faculty member at the Institute of Molecular Health Sciences , ETH Zurich . He leads the Tumor and Stem Cell Dynamics research group, focusing on dynamic cell identity in regeneration and cancer. Research Interests : Stem cell-environment interactions, organoid technology, single-cell sequencing, and mechanisms of tissue repair/tumorigenesis. Publications : 10+ articles (2015-2024) on organoid models, stem cell dynamics, and cancer biology.
Professor Stefan Maier holds the position of Head of School in Physics and Astronomy at Monash University. Previously, he served as the Lee Lucas Chair in Experimental Physics at Imperial College London (2007–2018) and built a new chair at Ludwig-Maximilians-Universität München (2019–2022). His research focuses on nanophotonics, plasmonics, and metasurface engineering, with emphasis on optical trapping, nonlinear optics, and novel photonic devices. Education: Bachelor’s degree in Physics, Technical University of Munich M.Sc. and Ph.D. in Applied Physics, California Institute of Technology (Caltech) Research Interests: Development of metamaterials and metasurfaces for light manipulation Applications of nanophotonics in sensing, imaging, and quantum technologies Optical trapping and plasmonic catalysis Nonlinear optical phenomena in nanostructured materials Articles Trends: Recent work emphasizes bound states in the continuum (BICs), 3D nanoprinted optical platforms, and active metasurfaces with tunable properties. Key themes include hybrid nanophotonics, ultra-high-Q resonators, and plasmonic nanomaterials for energy applications. Awards: ISI Highly Cited Researcher (2017–present) Grants/Projects: Chief Investigator in the All-on-chip twisted light modulator project (2022–2025) Leadership in Monash’s nanophotonics research team Labs/Teams: Directs a multidisciplinary lab at Monash focused on integrating 3D nanofabrication with optical physics, including collaborations in metafiber development and plasmonic biosensing.
Chang-Jun Liu is a Senior Scientist in the Plant Science Group of the Biology Department at Brookhaven National Laboratory, where he has conducted research on plant phenylpropanoid biosynthesis and lignin metabolism since joining in 2005. He also holds an Adjunct Professor position in the Biochemistry & Cell Biology Department at Stony Brook University and serves as Associate Editor for Plant Cell & Environment (2024-present) and Frontiers in Plant Sciences (2015-present). Dr. Liu's educational background includes: Ph.D. in Plant Biochemistry and Molecular Biology from the Shanghai Institute of Plant Physiology, Chinese Academy of Science (1999) Dr. Liu's research integrates approaches from biochemistry, molecular genetics, biophysics, protein engineering, metabolic engineering, and synthetic biology to investigate phenylpropanoid and lignin biosynthesis in plants. His laboratory addresses fundamental questions about how lignin and related compounds are synthesized and incorporated into cell walls, how regulatory networks govern metabolic activity, and how lignification influences cell wall structure and function. A central aim of his research is optimizing plant feedstocks for efficient lignocellulosic biomass utilization. Analysis of Dr. Liu's publication record reveals a consistent trajectory from fundamental biochemical mechanisms to applied bioenergy solutions. His recent work focuses on cytochrome b5 diversity, electron transfer mechanisms in phenolic biosynthesis, and metabolic engineering approaches to modify lignin composition. This research spans from evolutionary studies of lignin biosynthesis across plant lineages to practical applications in bioenergy crop improvement. Dr. Liu has received recognition for his contributions to science, including: Brookhaven National Laboratory Science and Technology Award (2018) Dr. Liu serves as Editorial Board Member for the Journal of Biological Chemistry (2020-present), PNAS Nexus (2024-present), and Plant Physiology Journal (2025-). He is Scientific Lead at the Joint BioEnergy Institute, Feedstocks Division, Lawrence Berkeley National Laboratory, and Project Lead at the Center for Bioenergy Innovation, Oak Ridge National Laboratory. His research is funded by the U.S. Department of Energy through multiple Bioenergy Research Centers. Dr. Liu leads a research group at Brookhaven National Laboratory focused on elucidating the posttranslational regulation and macromolecular organization of lignin biosynthesis, with applications toward developing designer lignins and reducing biomass recalcitrance for sustainable biofuel production. His work addresses the critical challenge of lignin's dual nature: while it impedes enzymatic access to polysaccharides in biofuel production, it also represents the most abundant renewable source of aromatic carbon for high-value bioproducts.
Manuel R. Amieva is a Professor at Stanford University School of Medicine , holding joint appointments in Pediatrics - Infectious Diseases and Microbiology & Immunology . He is also a member of the Maternal & Child Health Research Institute (MCHRI) . His clinical practice at Stanford Medicine Children's Health focuses on pediatric infectious diseases. Education: Medical Education: Stanford University School of Medicine (1997) Fellowship: Stanford University Pediatric Infectious Disease Fellowship (2004) Internship & Residency: Stanford Health Care at Lucile Packard Children's Hospital (1998-1999) Dr. Amieva's research investigates host-pathogen interactions at epithelial barriers, with specific expertise in Helicobacter pylori , Listeria monocytogenes , Salmonella enterica , and Staphylococcus aureus . His lab develops innovative organoid culture systems with controlled polarity to study microbial colonization and oncogenic mechanisms. Key discoveries include: H. pylori's manipulation of epithelial junctions via the CagA protein Listeria's exploitation of cell extrusion sites for invasion Staphylococcus toxin interactions with adherens junctions Gastric stem cell activation by pathogens Recent publication trends show continued leadership in infectious disease mechanisms (2020-2025), with a focus on: Pathogen-specific epithelial breach strategies Organoid modeling of viral/bacterial interactions Redox-dependent host factor regulation Single-cell spatial transcriptomic analyses Multi-institutional educational frameworks His scientific collaborations span disciplines including: Gastric cancer genomics initiatives COVID-19 lung infection models Stem cell-microbe interactions Medical education reform projects Dr. Amieva maintains active clinical research while mentoring students in both the Microbiology & Immunology and Pediatrics programs. His lab at Stanford employs advanced 3D confocal microscopy and organ-on-a-chip technologies to visualize epithelial colonization dynamics.
Professor John Pickett serves as Chair of the School of Chemistry at Cardiff University, where he holds the position of Professor of Biological Chemistry. His research program has established him as a leading figure in chemical ecology with significant contributions to understanding chemically mediated interactions between organisms. Professor Pickett's research focuses on chemical ecology involving chemically mediated interactions between various organisms, particularly pests attacking plants and animals. His work encompasses the chemical characterisation of pheromones and other semiochemicals across plants and animals, including insect pests and beneficial organisms. He investigates stress-related chemical signalling by plants and vertebrates (including humans and farm animals), elucidates biosynthetic pathways to pheromones and other semiochemicals, and explores how these compounds can be exploited in pest management through ecological approaches and genetic modification. Analysis of Professor Pickett's recent publications reveals a sustained and impactful research trajectory spanning chemical ecology, agricultural science, and sustainable development. His work demonstrates remarkable continuity in investigating semiochemicals and pheromones while expanding into interdisciplinary areas including AI applications for sustainable futures and the economic impacts of agricultural innovations. A consistent theme throughout his career is the practical application of chemical ecology principles to develop sustainable pest management solutions, particularly through the development and refinement of push-pull farming systems that have transformed agricultural practices in Africa.
Dewey G. McCafferty is Professor of Chemistry at Duke University with appointments in Biochemistry and the Duke Cancer Institute. His research focuses on chemical biology of chromatin-modifying enzymes and ubiquitin signaling pathways relevant to neurodegeneration and infection. Notable work includes discovering the lasso peptide antibiotic Arcumycin, characterizing the Nedd4 ubiquitin ligase in Parkinson's disease models, and developing chemoproteomic approaches for target identification. Key contributions include elucidation of the futalosine pathway in Chlamydia infections, mechanisms of CPAF protease in bacterial pathogenesis, and engineering of histone demethylase enzymes. McCafferty received the Eli Lilly Award in Biological Chemistry (2005) and directs NIH-funded projects on ubiquitin ligases in neurodegeneration.
David Allcock is an Assistant Professor in the Department of Physics at the University of Oregon, part of the College of Arts and Sciences. His research focuses on ion trapping, quantum computing, and hybrid quantum systems, with an emphasis on manipulating atomic and molecular systems using electric and magnetic fields for quantum information applications. He leads the Ion Trapping Lab at UO, where he develops scalable quantum technologies and open-source control systems like ARTIQ and Sinara. His work bridges experimental physics with engineering, addressing challenges in qubit control, error mitigation, and large-scale quantum computer design. Education: MPhys from the University of Oxford (2007), D.Phil. in Physics from Oxford (2012). Prior to UO, he was a Lindemann Fellow at the National Institute of Standards and Technology (NIST) in Boulder, CO. His research includes innovations in trapped-ion qubit control, including laser-free entangling gates, scalable architectures, and applications in quantum sensing and dark matter detection. Key research themes include metastable qubit systems, photon scattering error mitigation, and the integration of superconducting detectors for state readout. He collaborates on open-source hardware-software stacks for quantum experiments and mentors students in quantum engineering through programs like the Quantum Technology Master’s Internship. Current projects explore hybrid quantum-classical interfaces and ultra-stable ion trap fabrication. His lab’s contributions span theoretical and experimental domains, with recent advances in geometric phase gates, microwave-driven control, and error-resilient qubit operations. The group also engages in interdisciplinary work linking quantum computing with precision measurement, such as SPUD (SPectroscopy for Ultralight Dark matter) and bosonic sensing tools.
David Vocadlo is a Distinguished Professor of Chemistry and Molecular Biology & Biochemistry at Simon Fraser University (SFU), holding the Canada Research Chair in Chemical Biology. His research focuses on Chemical Glycobiology, investigating carbohydrate-processing enzymes and developing chemical tools to study glycan roles in health and disease. His lab explores O-GlcNAc signaling, neurodegenerative disorders (e.g., Alzheimer’s, Parkinson’s), and enzyme inhibitors for therapeutic applications. Education: PhD from University of British Columbia (UBC), followed by a CIHR postdoctoral fellowship at UC Berkeley. Key roles include E.W.R. Steacie Memorial Fellow and Royal Society Fellow. Research highlights include O-GlcNAcase inhibitors for neuroprotection, glycan structure-function relationships, and enzyme activity imaging tools. Collaborates globally with experts in glycobiology and employs cutting-edge techniques like chemical synthesis, mass spectrometry, and live-cell imaging. Awards: Distinguished Professor title, Canada Research Chair, Royal Society Fellowship. Active in training researchers through SFU’s graduate programs, emphasizing interdisciplinary approaches. Lab members work on topics ranging from enzyme mechanisms to disease modeling.
